Bharat Biotech completes clinical development for phase III trials, booster doses for BBV154 intranasal Covid vaccine

Aug 15, 2022

Hyderabad (Telangana) [India], August 15 : Bharat Biotech International on Monday said that BBV154 (intranasal vaccine) has proven to be safe, well-tolerated, and immunogenic...

Bharat Biotech gets SEC approval for phase 3 clinical trials of COVID booster intranasal vaccine

Jan 05, 2022

New Delhi [India], January 5 : The Subject Experts Committee (SEC) of the Drug Controller General of India (DCGI) on Wednesday granted approval to...

Bharat Biotech gets DCGI's nod to conduct intranasal booster dose trials

Jan 28, 2022

New Delhi [India], January 28 : The Drugs Controller General of India (DCGI) on Friday granted permission to Bharat Biotech to conduct clinical trials...

COVID-19: Bharat Biotech recruits 23,000 volunteers for COVAXIN's phase 3 clinical trial

Jan 02, 2021

Hyderabad (Telangana) [India], January 2 : Bharat Biotech has recruited 23,000 volunteers so far for the Phase III clinical trials of its COVID-19 vaccine...

Bharat Biotech seeks DCGI's approval for its intranasal COVID-19 booster dose clinical trials, submits application

Dec 20, 2021

New Delhi [India], December 20 : As India is witnessing a surge in cases of "highly transmissible" Omicron variant, Hyderabad-based Bharat Biotech has submitted...

Bharat Biotech's intranasal booster vaccine can be a game-changer if it provides mucosal immunity against COVID-19, says expert

Mar 11, 2022

New Delhi [India], March 11 : Bharat Biotech's intranasal booster vaccine can be a game-changer if it provides mucosal immunity against COVID-19, said Dr...